| 1.08 | 3.50% |
| SLXP Salix Pharmaceuticals Ltd. | Trade It Now | | NASDAQ |
| |
Market Cap 1.667B Book Value 7.093 EBITDA -27.2M Year Low 7.24 Year High 32.03 PEG Ratio 6.84 EPS -0.884 P/B Ratio 4.35 Short Ratio 3.30 Index Membership S&P 600 SmallCap S&P  Sector Healthcare Industry Drug Related Products Open 30.94 High 32.00 Low 30.5985 Last Close 30.88 Volume 1.8 M Target Price 41.33 Current EPS -0.884 This Year EPS 0.11 Next Year EPS 1.46 This Year PE 280.73 Next Year PE 21.15 Salix Pharmaceuticals Ltd.1700 Perimeter Park Drive Morrisville,
NC 27560-8404 United States - Map
Phone: 919-862-1000
Fax: 919-862-1095
Web Site: VisitType: Stock | | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars—Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| |
Options Activity for Salix Pharmaceuticals, (SLXP)
Market Intellisearch - Mar 11, 2010
SLXP options saw interesting call activity today. A total of 505 put and 7,283 call contracts were traded raising a low Put/Call volume alert. Today's traded Put/Call ratio is 0.07. There were 14 ...
2010-03-11 |  | |
| | | 2010-03-10 |  | |
| | |
Salix Pharmaceuticals Guides Below Estimates
Trading Markets - Mar 9, 2010
Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) said it expects a first quarter loss of $0.50 per share with total product revenue of $40.0 million. The current consensus estimate is a loss of $0.07 per ...
2010-03-09 |  | |
| | | 2010-03-09 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-03-13 |  | |
|
Community Discussions | | | (0.09) | 1.05% |
| PBH Prestige Brands Holdings Inc. | Trade It Now | | NYSE |
| |
Market Cap 425.7M Book Value 6.493 EBITDA 100.1M Year Low 4.00 Year High 8.90 PEG Ratio 1.00 EPS -3.645 P/B Ratio 1.32 Short Ratio 6.60 Sector Healthcare Full Time Employees 98 Industry Drug Related Products Open 8.65 High 8.67 Low 8.42 Last Close 8.60 Volume 162.1 K Target Price 10.67 Current EPS -3.645 This Year EPS 0.78 Next Year EPS 0.84 This Year PE 11.03 Next Year PE 10.24 Prestige Brands Holdings Inc.90 North Broadway Irvington,
NY 10533 United States - Map
Phone: 914-524-6810
Fax: 914-524-6815
Web Site: VisitType: Stock | | Prestige Brands Holdings, Inc., together with its subsidiaries, engages in the marketing, sale, and distribution of over-the-counter healthcare, household cleaning, and personal care products primarily in the United States and Canada. |
Company Summary more  Prestige Brands Holdings, Inc., together with its subsidiaries, engages in the marketing, sale, and distribution of over-the-counter healthcare, household cleaning, and personal care products primarily in the United States and Canada. The company’s Over-The-Counter Healthcare segment offers treatments for sore throat relief, eye redness relief, wart removal, bruxism, oral care, pediatric healthcare, personal ear care, liquid bandages, and pain relief sprays. It offers these products under the Clear Eyes, Murine, Chloraseptic, Compound W, Wartner, Little Remedies, The Doctor’s NightGuard, New-Skin, Dermoplast, Percogesic, Momentum, Mosco, Outgro, Sleep-Eze, and Compoz brand names. Prestige Br... Prestige Brands Holdings, Inc., together with its subsidiaries, engages in the marketing, sale, and distribution of over-the-counter healthcare, household cleaning, and personal care products primarily in the United States and Canada. The company’s Over-The-Counter Healthcare segment offers treatments for sore throat relief, eye redness relief, wart removal, bruxism, oral care, pediatric healthcare, personal ear care, liquid bandages, and pain relief sprays. It offers these products under the Clear Eyes, Murine, Chloraseptic, Compound W, Wartner, Little Remedies, The Doctor’s NightGuard, New-Skin, Dermoplast, Percogesic, Momentum, Mosco, Outgro, Sleep-Eze, and Compoz brand names. Prestige Brands Holdings’ Household Cleaning segment markets household cleaning products, such as abrasive and non-abrasive tub and tile cleaner, soap free metal scrubbers and sponges, and dilutable all purpose cleaning products under the Comet, Chore Boy, and Spic and Span brands. The company’s Personal Care segment offers Cutex nail products, EZO denture cushion, Oxipor, Cloverine skin salve, and Kerodex barrier cream. It sells products through various channels, including mass merchandisers, drug, grocery, and dollar and club stores. Prestige Brands Holdings was founded in 1996 and is headquartered in Irvington, New York. Prestige Brands Holdings, Inc., together with its subsidiaries, engages in the marketing, sale, and distribution of over-the-counter healthcare, household cleaning, and personal care products primarily in the United States and Canada. The company’s Over-The-Counter Healthcare segment offers treatments for sore throat relief, eye redness relief, wart removal, bruxism, oral care, pediatric healthcare, personal ear care, liquid bandages, and pain relief sprays. It offers these products under the Clear Eyes, Murine, Chloraseptic, Compound W, Wartner, Little Remedies, The Doctor’s NightGuard, New-Skin, Dermoplast, Percogesic, Momentum, Mosco, Outgro, Sleep-Eze, and Compoz brand names. Prestige Br... Top Stories| |
Prestige Brands To Offer $150 Million Of Senior Notes
Trading Markets - Mar 11, 2010
March 11, 2010 (FinancialWire) -- Prestige Brands Holdings, Inc. (NYSE: PBH) said that its wholly-owned subsidiary Prestige Brands, Inc., is making a private placement offering of $150 million in ...
2010-03-11 |  | |
| | |
New Issue-Prestige Brands Inc sells $150 mln notes
Reuters - Mar 10, 2010
March 10 (Reuters) - Prestige Brands Inc (PBH.N) on Wednesday sold $150 million of senior notes in the 144a private placement market, said IFR, a Thomson Reuters service. Bank of America Merrill ...
2010-03-10 |  | |
| | | 2010-03-10 |  | |
| | | 2010-03-10 |  | |
|
Community Discussions |